Ceva Santé Animale S.A.

Ceva Santé Animale S.A.

Ceva Santé Animale was founded in 1999 through the merger of three French animal health units — from Rhône-Poulenc (later Sanofi), Vétoquinol, and the veterinary division of the Institut Mérieux. Dr. Marc Prikazsky, a veterinarian by training, has served as Chairman and CEO since the company's inception, building Ceva into a privately held global enterprise. The company's strategy blends internal R&D with targeted acquisitions across vaccines, pharmaceuticals, and diagnostics. Ceva operates in over 110 countries with direct subsidiaries in 47, supported by manufacturing sites in France, Spain, the U.S., Brazil, and Hungary. The firm has completed more than 30 acquisitions since founding, including the 2021 purchase of the animal health business of Germany's Dopharma and the 2020 integration of Australia's Apex Laboratories. Ceva employs roughly 2,300 professionals globally, with R&D centers in France and the U.S. The company is backed by its founding family and other institutional shareholders; it has not disclosed outside capital raises. Ceva sponsors philanthropic initiatives focused on veterinary education and livestock health in developing regions. In October 2023, Ceva acquired the poultry vaccine business of Germany's IDT Biologika, expanding its avian influenza portfolio (per the firm, October 2023). Ceva's structural differentiator is its dual focus on both commercial livestock (poultry, swine, cattle) and companion animals (dogs, cats), combined with a vertically integrated manufacturing base. Unlike many animal health firms that are divisions of large pharma conglomerates, Ceva remains an independent, founder-led pure play — a structure that allows rapid decision-making and operational agility in a regulated global market.